Literature DB >> 10841077

Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines.

J J Kim1, J S Yang, T Dentchev, K Dang, D B Weiner.   

Abstract

Nucleic acid immunization has been shown to induce both antigen-specific cellular and humoral immune responses in vivo. Moreover, immune responses induced by DNA immunization can be enhanced by the use of molecular adjuvants. For example, coadministration of costimulatory molecules (CD80 and CD86), proinflammatory cytokines (interleukin-1alpha [IL-1alpha], tumor necrosis factor-alpha [TNF-alpha, and TNF-beta), Th1 cytokines (interleukin-2 [IL-2], IL-12, IL-15, and IL-18), Th2 cytokines (IL-4, IL-5, and IL-10), and granulocytes-macrophage colony-stimulating factor (GM-CSF) with DNA vaccine constructs leads to modulation of the magnitude and direction (humoral or cellular) of the immune responses. To further engineer the immune response in vivo, we compared the induction and regulation of immune responses from the codelivery of chemokine (IL-8, interferon-gamma-inducible protein-10 [gammaIP-10], macrophage inhibitory protein-1alpha [MIP-1alpha], and RANTES) genes with codelivery of cytokine genes. We found that as in cytokine gene codelivery, coimmunization with chemokine genes along with DNA immunogen constructs can modulate the direction and magnitude of induced immune responses. We observed that coimmunization with IL-8, gammaIP-10, and MIP-1alpha genes increased the antibody response. We also found that coinjection with IL-8, gammaIP-10, and RANTES resulted in a dramatic enhancement of T helper (Th) proliferation response. Furthermore, among all coinjection combinations, we found that RANTES coinjection caused a high level of cytotoxic lymphocyte (CTL) enhancement. This enhancement of CTL responses observed from the coinjection with RANTES was CD8+ T cell dependent. Together with earlier reports on the utility of coimmunizing immunologically important molecules with DNA immunogens, we demonstrate the potential of this strategy as an important tool for the development of more rationally designed vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841077     DOI: 10.1089/10799900050023906

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  18 in total

1.  Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4.

Authors:  Afzal A Siddiqui; Troy Phillips; Hugues Charest; Ron B Podesta; Martha L Quinlin; Justin R Pinkston; Jenny D Lloyd; Michelle Paz; Rachael M Villalovos; Janet Pompa
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

2.  Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines.

Authors:  Ruijiang Song; Shuqin Liu; Kam W Leong
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

3.  Natural killer cells that respond to human immunodeficiency virus type 1 (HIV‐1) peptides are associated with control of HIV‐1 infection.

Authors:  Caroline T Tiemessen; Sharon Shalekoff; Stephen Meddows-Taylor; Diana B Schramm; Maria A Papathanasopoulos; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

4.  Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; Xiuli Zhang; Olivia K Giddings; Thomas E Lane; Daniel F Hoft
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

5.  Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.

Authors:  Noshin Kathuria; Kimberly A Kraynyak; Diane Carnathan; Michael Betts; David B Weiner; Michele A Kutzler
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

6.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

7.  Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

Authors:  Kimberly A Kraynyak; Michele A Kutzler; Neil J Cisper; Amir S Khan; Ruxandra Draghia-Akli; Niranjan Y Sardesal; Mark G Lewis; Jian Yan; David B Weiner
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

Review 8.  Developing DNA vaccines that call to dendritic cells.

Authors:  Michele A Kutzler; David B Weiner
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 9.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Diana B Schramm; Samantha L Donninger; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.